Story thread · 2 reports / 2 sources
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
endpts.com · 8h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer. The companies’ oral drug, called zipalertinib, plus ...
The coverage
- New Taiho, Cullian data heats up lung cancer drug battle
biopharmadive.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.